The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia

Fundamental and Clinical Pharmacology

Volumn 26, Issue 3, 2012, Pages 424-431

  Krysiak, Robert ^a   Zmuda, Witold ^b   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Invasive Cardiology Electrotherapy and Angiology Centre   (Poland)

Author keywords

Ezetimibe; Factor VII; Factor X; Fibrinogen; Hypercholesterolemia; Plasminogen activator inhibitor 1; Simvastatin; Von Willebrand factor

Indexed keywords

AMINOTRANSFERASE; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; EZETIMIBE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIMVASTATIN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BEDTIME DOSAGE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; AZETIDINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOSTASIS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SIMVASTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860255792     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00932.x     Document Type: Article

References (30)

1. Catapano A.L. Perspectives on low-density lipoprotein cholesterol goal achievement. Curr. Med. Res. Opin. (2009) 25 431-447.
2. Davidson H. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler. Rep. (2009) 1 67-70.
3. Filippatos T.D., Mikhailidis D.P. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr. Pharm. Des. (2009) 15 490-516.
4. Miura S., Saku K. Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern. Med. (2008) 47 1165-1170.
5. Yagi S., Akaike M., Aihara K. et al. Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J. Atheroscler. Thromb. (2010) 17 173-180.
6. Shaw S.M., Najam O., Khan U., Yonan N., Williams S.G., Fildes J.E. Ezetimibe and atorvastatin both immunoregulate CD4+ T cells from cardiac transplant recipients in vitro. Transpl. Immunol. (2009) 211 79-82.
7. Orsó E., Werner T., Wolf Z. et al. Ezetimib influences the expression of raft-associated antigens in human monocytes. Cytometry A (2006) 69 206-208.
8. Bays H.E., Neff D., Tomassini J.E. et al. Ezetimibe: cholesterol lowering and beyond. Expert Rev. Cardiovasc. Ther. (2008) 6 447-470.
9. Kher N., Marsh J.D. Pathobiology of atherosclerosis - a brief review. Semin. Thromb. Hemost. (2004) 30 665-672.
10. Saigo M., Hsue P.Y., Waters D.D. Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog. Cardiovasc. Dis. (2004) 465 524-538.
11. Kannel W.B. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids (2005) 40 1215-1220.
12. Krysiak R., Okopien B., Herman Z.S. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs (2003) 63 1821-1854.
13. Turfaner N., Uzun H., Balci H. et al. Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. South. Med. J. (2010) 103 428-433.
14. Pitsavos C., Skoumas I., Tousoulis D. et al. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia. Int. J. Cardiol. (2009) 134 280-281.
15. Kostakou P., Kolovou G., Anagnostopoulou K. et al. Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia. Arch. Cardiovasc. Dis. (2010) 103 26-32.
16. Yamamoto K., Shibayama S., Takeshita K., Kojima T., Takamatsu J. A novel cholesterol absorption inhibitor, ezetimibe, decreases adipose-derived and vascular PAI-1 expression in vivo. Thromb. Res. (2009) 124 644-645.
17. Piorkowski M., Fischer S., Stellbaum C. et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J. Am. Coll. Cardiol. (2007) 49 1035-1042.
18. Malmström R.E., Settergren M., Böhm F., Pernow J., Hjemdahl P. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance. Thromb. Haemost. (2009) 101 157-164.
19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360 7-22.
20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study Group. Lancet (1994) 344 1383-1389.
21. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. (1995) 333 1301-1307.
22. Krysiak R., Okopien B. The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J. Cardiovasc. Pharmacol. (2011) Feb 3. [Epub ahead of print].
23. Kastelein J.J., Akdim F., Stroes E.S. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. (2008) 358 1431-1443.
24. Rossebo A.B., Pedersen T.R., Boman K. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. (2008) 359 1343-1356.
25. Kita T., Kume N., Minami M. et al. Role of oxidized LDL in atherosclerosis. Ann. N Y Acad. Sci. (2001) 947 199-205.
26. Jasinska M., Owczarek J., Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol. Rep. (2007) 59 483-499.
27. Dahlback B. Blood coagulation. Lancet (2000) 355 1627-1632.
28. Seedorf U., Engel T., Lueken A. et al. Cholesterol absorption inhibitor ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem. Biophys. Res. Commun. (2004) 320 1337-1341.
29. Wilson H.M., Barker R.N., Erwig L.P. Macrophages: promising targets for the treatment of atherosclerosis. Curr. Vasc. Pharmacol. (2009) 7 234-243.
30. Hickmott H., Wynne H., Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb. Haemost. (2003) 89 949-950.